Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein

Journal of Hepatology

Volumn 51, Issue 3, 2009, Pages 520-527

  Mansilla, Cristina ^a   Gorraiz, Marta ^a   Martinez, Marta ^a   Casares, Noelia ^a   Arribillaga, Laura ^a   Rudilla, Francesc ^a   Echeverria, Iciar ^a   Riezu Boj, José Ignacio ^a   Sarobe, Pablo ^a   Borrás Cuesta, Francisco ^a   Prieto, Jesús ^a   Lasarte, Juan José ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Adjuvant; Dendritic cell; EDA; Hepatitis C; Vaccine

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; FIBRONECTIN; HLA A2 ANTIGEN; HYBRID PROTEIN; INTERLEUKIN 12; NONSTRUCTURAL PROTEIN 3; NOTCH RECEPTOR; POLYINOSINIC POLYCYTIDYLIC ACID; RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ESCHERICHIA COLI; GENE EXPRESSION; HEPATITIS C VIRUS; IN VITRO STUDY; IN VIVO CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; TRANSGENIC MOUSE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELLS, CULTURED; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; FEMALE; FIBRONECTINS; HEPACIVIRUS; HEPATITIS C; HLA-A2 ANTIGEN; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; POLY I-C; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; RNA, VIRAL; VIRAL FUSION PROTEINS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 68049118550     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.06.005     Document Type: Article

References (37)

1. Stoll-Keller F., Barth H., Fafi-Kremer S., Zeisel M.B., and Baumert T.F. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines 8 (2009) 333-345
2. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5 (2005) 215-229
3. Diepolder H.M., Zachoval R., Hoffmann R.M., Wierenga E.A., Santantonio T., Jung M.C., et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346 (1995) 1006-1007
4. Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 6 (2006) 476-483
5. Cuadros C., Lopez-Hernandez F.J., Dominguez A.L., McClelland M., and Lustgarten J. Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun 72 (2004) 2810-2816
6. Lasarte J.J., Casares N., Gorraiz M., Hervas-Stubbs S., Arribillaga L., Mansilla C., et al. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J Immunol 178 (2007) 748-756
7. LeibundGut-Landmann S., Gross O., Robinson M.J., Osorio F., Slack E.C., Tsoni S.V., et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 8 (2007) 630-638
8. Tighe H., Takabayashi K., Schwartz D., Marsden R., Beck L., Corbeil J., et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 30 (2000) 1939-1947
9. Ahonen C.L., Doxsee C.L., McGurran S.M., Riter T.R., Wade W.F., Barth R.J., et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 199 (2004) 775-784
10. Wen T., Bukczynski J., and Watts T.H. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol 168 (2002) 4897-4906
11. Ahlers J.D., Belyakov I.M., and Berzofsky J.A. Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr Mol Med 3 (2003) 285-301
12. Alexopoulou L., Holt A.C., Medzhitov R., and Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 (2001) 732-738
13. Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier F.A., and Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185 (1997) 2043-2051
14. Cerny A., McHutchison J.G., Pasquinelli C., Brown M.E., Brothers M.A., Grabscheid B., et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 95 (1995) 521-530
15. Vishnuvardhan D., Kakiuchi N., Urvil P.T., Shimotohno K., Kumar P.K., and Nishikawa S. Expression of highly active recombinant NS3 protease domain of hepatitis C virus in E. coli. FEBS Lett 402 (1997) 209-212
16. Zabala M., Lasarte J.J., Perret C., Sola J., Berraondo P., Alfaro M., et al. Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J Hepatol 47 (2007) 807-815
17. Durantez M., Lopez-Vazquez A.B., de Cerio A.L., Huarte E., Casares N., Prieto J., et al. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes. Scand J Immunol 69 (2009) 80-89
18. Zabaleta A., Arribillaga L., Llopiz D., Dotor J., Lasarte J.J., Prieto J., et al. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40. Antiviral Res 74 (2007) 25-35
19. Amsen D., Blander J.M., Lee G.R., Tanigaki K., Honjo T., and Flavell R.A. Instruction of distinct CD4 T helper cell fates by different Notch ligands on antigen-presenting cells. Cell 117 (2004) 515-526
20. Llopiz D., Dotor J., Zabaleta A., Lasarte J.J., Prieto J., Borras-Cuesta F., et al. Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects. Cancer Immunol Immunother 57 (2008) 19-29
21. Audibert F.M., and Lise L.D. Adjuvants: current status, clinical perspectives and future prospects. Immunol Today 14 (1993) 281-284
22. Seong S.Y., and Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 4 (2004) 469-478
23. Bonifaz L., Bonnyay D., Mahnke K., Rivera M., Nussenzweig M.C., and Steinman R.M. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196 (2002) 1627-1638
24. Steinman R.M., Hawiger D., and Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 21 (2003) 685-711
25. Bourgeois C., Rocha B., and Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 297 (2002) 2060-2063
26. Lefrancois L., Altman J.D., Williams K., and Olson S. Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells. J Immunol 164 (2000) 725-732
27. Kolumam G.A., Thomas S., Thompson L.J., Sprent J., and Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202 (2005) 637-650
28. Tough D.F., Borrow P., and Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272 (1996) 1947-1950
29. Lapointe R., Toso J.F., Butts C., Young H.A., and Hwu P. Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes. Eur J Immunol 30 (2000) 3291-3298
30. Schulz O., Edwards A.D., Schito M., Aliberti J., Manickasingham S., Sher A., et al. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 13 (2000) 453-462
31. Gelman A.E., Zhang J., Choi Y., and Turka L.A. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol 172 (2004) 6065-6073
32. Sivori S., Falco M., Della Chiesa M., Carlomagno S., Vitale M., Moretta L., et al. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci USA 101 (2004) 10116-10121
33. Maekawa Y., Tsukumo S., Chiba S., Hirai H., Hayashi Y., Okada H., et al. Delta1-Notch3 interactions bias the functional differentiation of activated CD4+ T cells. Immunity 19 (2003) 549-559
34. Sun J., Krawczyk C.J., and Pearce E.J. Suppression of Th2 cell development by Notch ligands Delta1 and Delta4. J Immunol 180 (2008) 1655-1661
35. Skokos D., and Nussenzweig M.C. CD8-DCs induce IL-12-independent Th1 differentiation through Delta 4 Notch-like ligand in response to bacterial LPS. J Exp Med 204 (2007) 1525-1531
36. Akira S., and Takeda K. Toll-like receptor signalling. Nat Rev Immunol 4 (2004) 499-511
37. Bishop G.A., Moore C.R., Xie P., Stunz L.L., and Kraus Z.J. TRAF proteins in CD40 signaling. Adv Exp Med Biol 597 (2007) 131-151